TT701 is a promising SARM candidate that’s already going through its Phase-II clinical trials of developmental testing these days. Find out all you need to know about this compound when you follow along.

A Quick Look at TT701

TT701 is a type of selective androgen receptor modulator or SARM in the works that is mainly designed to help men with prostate cancer, particularly those who already went through radical prostatectomy for organ-localized prostate cancer.

These men tend to be highly prone to a very sharp drop in their testosterone levels that can lead to adverse effects like chronic fatigue as well as weakened or loss of sexual performance. This compound is also formulated to help improve the quality of life among prostate cancer survivors who are vulnerable to various issues in terms of physical dysfunction.

Just to give you a little background, prostate cancer is among the most common of malignant form of cancer in the United States and accounts 29% of all diagnosed cancers and 13% of mortalities brought on by the disease.

TT701 has already been set to be administered in a clinical study with Brigham and Women’s Hospital in Boston, Massachusetts to test its efficacy against prostate cancer. The study will be headed by Dr. Shalender Bhasin and is expected to have as much as 125 participants.

Who’s Responsible for TT701?

This promising SARM candidate is initiated by Transition Therapeutics Inc., a biopharmaceutical development company. Rights to the compound have been licensed to Eli Lilly and Company.

Learn more about the most popular SARMs and related compounds available these days like S4 (Andarine), Ostarine (MK-2866), LGD-4033 and GW 501516 (Cardarine).



  • ClassErectile dysfunction therapies; Small molecules
  • Mechanism of ActionSelective androgen receptor modulators; Testosterone replacements
  • Highest Development Phases

    • Phase IIBenign prostatic hyperplasia; Erectile dysfunction; Prostate cancer

    Most Recent Events

    • 04 Feb 2019OPKO Health plans a phase II trial in Renal failure
    • 31 Jan 2019OPKO Health plans to discontinue a phase II trial in Benign prostatic hyperplasia in USA owing to an unfavourable outcome from review of blinded data (PO)
    • 31 Jan 2019OPKO Health plans a phase II trial in Prostate cancer (Second-line therapy or greater)